| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Multiple targets including microtubules and cancer cell signaling pathways. Neoanhydropodophyllol, as a cyclolignan derivative, exhibits potent antineoplastic activity by exerting cytotoxic effects on various cancer cell lines. The compound's mechanism of action is likely related to its structural similarity to podophyllotoxin, which binds to tubulin and inhibits microtubule polymerization, leading to cell cycle arrest in the G2/M phase and induction of apoptosis. Cyclolignans may also inhibit topoisomerase II and other enzymes involved in DNA replication and cell division. The compound's cytotoxicity against leukemia, lung carcinoma, and colon carcinoma suggests broad-spectrum anticancer activity.
|
|---|---|
| ln Vitro |
Neoanhydropodophyllol displays cytotoxicity against several cancer cells, including leukemia, lung carcinoma, and colon carcinoma. As a cyclolignan derivative, it exhibits potent antineoplastic activity. The compound's cytotoxic effects are attributed to its ability to interfere with microtubule dynamics or other cellular processes essential for cancer cell proliferation and survival. The compound's activity against multiple cancer cell lines suggests broad-spectrum anticancer potential. It is structurally related to podophyllotoxin and other cyclolignans with well-established anticancer properties.
|
| ln Vivo |
In vivo studies of neoanhydropodophyllol are limited. As a cyclolignan with antineoplastic activity, it has potential for evaluation in animal models of cancer. The compound's cytotoxicity against leukemia, lung carcinoma, and colon carcinoma suggests that it may have efficacy in xenograft models of these cancers. However, specific in vivo data are not well documented in the published literature. Further studies are needed to characterize its in vivo pharmacokinetic and pharmacodynamic properties, as well as its efficacy and safety profile.
|
| Enzyme Assay |
Non-cell-based assays for neoanhydropodophyllol include enzyme inhibition studies to assess its effects on tubulin polymerization, topoisomerase II activity, or other molecular targets. Tubulin polymerization assays measure the compound's ability to inhibit or promote microtubule assembly in vitro using purified tubulin and spectrophotometric detection. Topoisomerase II inhibition assays measure the compound's ability to inhibit DNA relaxation or decatenation activity. Standard analytical methods including HPLC, NMR, and mass spectrometry are used for compound characterization.
|
| Cell Assay |
Cell-based assays for neoanhydropodophyllol use various cancer cell lines, including leukemia (e.g., K562, HL-60), lung carcinoma (e.g., A549, H460), and colon carcinoma (e.g., HT-29, HCT116). Cells are cultured in appropriate medium and treated with neoanhydropodophyllol at various concentrations. Cell viability is measured using MTT, CCK-8, or SRB assays. Apoptosis is evaluated by flow cytometry using Annexin V/PI staining, caspase activity assays, and detection of apoptotic markers by Western blot. Cell cycle analysis is performed by propidium iodide staining and flow cytometry.
|
| Animal Protocol |
In vivo studies of neoanhydropodophyllol are limited. Based on its cytotoxic activity against various cancer cell lines, potential animal models include: mouse xenograft models bearing leukemia, lung carcinoma, or colon carcinoma cells. Standard protocols for xenograft studies involve subcutaneous implantation of cancer cells in immunodeficient mice, followed by administration of the compound (typically intraperitoneal or intravenous) when tumors reach a certain size. Tumor volume is measured over time, and tissues are collected for histopathological examination and biomarker analysis.
|
| ADME/Pharmacokinetics |
Neoanhydropodophyllol has a molecular formula of C₂₂H₂₄O₇ and a molecular weight of approximately 400.42 g/mol. It is a cyclolignan derivative with antineoplastic activity. The compound is soluble in organic solvents such as DMSO. It should be stored as a powder at -20°C for up to 3 years or in solvent at -80°C for 1 year. It is intended for research use only and is not for human consumption. Specific solubility and formulation information may vary and should be determined experimentally.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for neoanhydropodophyllol are limited. As a cyclolignan with antineoplastic activity, it is expected to have cytotoxic effects on both cancer cells and normal cells at high concentrations. The compound's mechanism of action may involve interference with microtubule dynamics, which can affect normal cell division. Standard laboratory safety practices should be followed when handling this compound, including the use of personal protective equipment. It is intended for research use only.
|
| References | |
| Additional Infomation |
Neoanhydropodophyllol is a cyclolignan derivative with potent antineoplastic activity. Cyclolignans are a class of natural products characterized by a dibenzylbutyrolactone skeleton, with podophyllotoxin being the most well-known member. These compounds are known for their ability to inhibit microtubule polymerization and topoisomerase II, leading to cell cycle arrest and apoptosis in cancer cells. Neoanhydropodophyllol displays cytotoxicity against leukemia, lung carcinoma, and colon carcinoma, making it a compound of interest for anticancer research. It is structurally related to other cyclolignans with established clinical applications, such as etoposide and teniposide. The compound is for research use only.
|
| Molecular Formula |
C22H24O7
|
|---|---|
| Molecular Weight |
400.421767234802
|
| Exact Mass |
400.152
|
| CAS # |
62287-47-2
|
| PubChem CID |
44272112
|
| Appearance |
White to off-white solid powder
|
| Source |
Originated from plants: Berberidaceae Dysosma versipellis (Hance) M. Cheng ex Ying
|
| LogP |
2.4
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
29
|
| Complexity |
559
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
O1C[C@@H]2[C@H](C3C=C(C(=C(C=3)OC)OC)OC)C3C=C4C(=CC=3[C@H]1[C@H]2CO)OCO4
|
| InChi Key |
GAPFRQMOPFLDIS-YJPXFSGGSA-N
|
| InChi Code |
InChI=1S/C22H24O7/c1-24-18-4-11(5-19(25-2)22(18)26-3)20-12-6-16-17(29-10-28-16)7-13(12)21-14(8-23)15(20)9-27-21/h4-7,14-15,20-21,23H,8-10H2,1-3H3/t14-,15-,20+,21-/m0/s1
|
| Chemical Name |
[(1R,11R,12R,15R)-11-(3,4,5-trimethoxyphenyl)-5,7,14-trioxatetracyclo[10.2.1.02,10.04,8]pentadeca-2,4(8),9-trien-15-yl]methanol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (249.74 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (3.12 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (3.12 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 1.25 mg/mL (3.12 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4974 mL | 12.4869 mL | 24.9738 mL | |
| 5 mM | 0.4995 mL | 2.4974 mL | 4.9948 mL | |
| 10 mM | 0.2497 mL | 1.2487 mL | 2.4974 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
